
-
Australia on brink of World Cup as Indonesia end China hopes
-
China's World Cup hopes over with 1-0 Indonesia defeat
-
Sabalenka downs Swiatek as Boisson eyes 'dream' French Open final
-
Colombian cycling star 'Lucho' Herrera questioned over murder conspiracy
-
Stocks rise as Trump, Xi speak amid trade tensions
-
Como block Inter move for Fabregas
-
Sabalenka dethrones Swiatek to reach first French Open final
-
Trump, Xi hold long-awaited phone call on trade war
-
Cannes red carpet gets second life as handbags, hats or slippers
-
Jury prepares to consider Harvey Weinstein verdict
-
What is genocide and is it happening in Gaza?
-
England hope to have Archer back against India after lengthy lay-off
-
US trade gap plummets as Trump tariffs take hold
-
Ait-Nouri, Reijnders to join Man City for Club World Cup - reports
-
No England crisis ahead of Euros despite absence of star trio: Wiegman
-
ECB cuts rates again but pause seen ahead
-
TotalEnergies in landmark greenwashing trial in France
-
Indigenous rights defender elected head of top Mexican court
-
Stocks slide as Trump, Xi speak amid trade tensions
-
Dr Martens seeks more stability after new profit slide
-
Japan scrum-half Saito extends Toulouse deal
-
Turkmenistan reduces 50-year fire dubbed 'Gateway to Hell'
-
England paceman Carse considered amputation of troublesome toe
-
Australia on brink of World Cup after dramatic late winner
-
Germany's Merz to brave Trump's Oval Office test
-
Restaurants strike on popular Greek tourist island over beach clampdown
-
Greenpeace activists charged with theft of Macron waxwork
-
US trade deficit sharply narrows in April as Trump tariffs take hold
-
US says NATO close to agreeing to Trump's spending demand
-
ECB cuts rate again facing growth, tariff woes
-
Ailing Baltic Sea in need of urgent attention
-
Erasmus unveils monster Springbok squad for Tests against Baa-Baas, Italy and Georgia
-
Afghan women UN staff forced to work from home after threats
-
Bengaluru offer cash help after deadly India cricket stampede
-
First ever Birkin bag to be auctioned in July
-
New Rangers boss Martin aims to win over fans as he targets Celtic crown
-
US says NATO close to agreeing to Trump's defence spending demand
-
Brazil's Lula urges Macron to seal Mercosur trade deal
-
Japanese startup attempts Moon landing
-
Osaka, Pegula pull out of historic women's event at Queen's
-
Muslim pilgrims pray, shirk sun, as hajj reaches peak
-
Clean energy investment rising despite economic uncertainty: IEA
-
Greenpeace slams Coca-Cola for producing billions of plastic bottles
-
Swiatek faces Sabalenka as Boisson eyes 'dream' French Open final
-
Eurozone stocks climb before ECB rate decision
-
Iranians' World Cup dream crushed by US travel ban
-
Australia says China anxiety, geography driving closer Indonesia ties
-
'Hurt': Ukrainians in Poland worried by rise of nationalists
-
Overton, Bethell back in England Test squad for first India Test
-
New Zealand parliament gives record bans to Maori MPs over haka

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
Interviews with participating patients from the VenoValve® U.S. Pivotal Trial
Webcast replay from with the presenting Primary Investigators
Presentation with data from the VenoValve U.S. Pivotal Trial
Access the Recap Website Here!
enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium. Materials accessible on the recap website include interviews with two patients and two Principal Investigators who participated in the VenoValve U.S. Pivotal Trial as well as data presented at the symposium.

"While our data is compelling, we think it is equally important to hear the stories behind the data from both physicians and patients who have first-hand experience with the VenoValve," said Robert Berman, enVVeno Medical's Chief Executive Officer. "It is physicians and patients that will ultimately drive our commercial success following FDA approval. This is the second group of patients and third group of primary investigators whose perspectives we have made available. It takes an organic network of physician and patient advocates for a new device to succeed and anyone who takes the time to engage with these materials will recognize the strong foundation we've established."
Access the enVVeno Medical VEITH Symposium Recap Site at envveno.com/veith-2024
Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year.
The VenoValve® is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company is also developing enVVe®, a next-generation, transcatheter based replacement venous valve, that could appeal to an even larger market in terms of both patients and physicians.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
###
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
SOURCE: enVVeno Medical Corporation
O.M.Souza--AMWN